Categories: News

Overview of the deadlines at which shares of AS Olainfarm will be excluded from the regulated market:

Overview of the deadlines at which shares of AS Olainfarm will be excluded from the regulated market:

  1. The period of the share buy-back offer began on 08.11.2021.
  2. The period of the share buy-back offer will end on 07.12.2021.
  3. Within 5 working days (until 14.12.2021.), a report on the results of the share buy-back offer will be published in the official publication Latvijas Vēstnesis and payments of shares will be made with shareholders that have accepted the share buy-back offer.
  4. Not earlier than 10 (until 29.12.2021.) and not later than 15 working days (until 06.01.2022) from the date on which the report on the results of the offer was published in the official publication Latvijas Vēstnesis AS Olainfarm will submit an application to the Nasdaq Riga stock exchange regarding the exclusion of shares from the stock exchange.
  5. Within 10 working days (until 20.01.2021.) management board of the Nasdaq Riga stock exchange will take a decision on the exclusion of the shares of AS Olainfarm from the stock exchange.

Additional information:  
Jānis Leimanis
JSC Olainfarm Member of Management Board
Phone: +371 29269424
Email: janis.leimanis@olainfarm.com

Staff

Recent Posts

Financière de Tubize – Annual report 2023

FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: investorrelations@financiere-tubize.be Annual Report…

21 hours ago

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP…

21 hours ago

Ibogaine By David Dardashti Leverages Albert Einstein’s Corelation Between Photon Particles and Quantum Electrodynamics

Ibogaine By David Dardashti Revolutionizes Solar Energy Efficiency Through Radiation Generators Einstein A young and…

21 hours ago

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…

21 hours ago

NurExone’s Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX)…

21 hours ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…

21 hours ago